Company: RCUS
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001193125-25-028669
Chunk: 4

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 4
---
 |     | Safetyf          |     |                  |     |                   |
| Any Serious Treatment-Emergent Adverse Events (TEAEs) related to casdatifan |     | 3% (1)           |     | 10% (3)          |     | 7% (2)            |
| Grade ≥3 TEAEs related to casdatifan                                        
 Anemia Hypoxia                                                              |     | 42% (14)         
 9% (3)           |     | 32% (10)         
 7% (2)           |     | 17% (5)           
 10% (3)           |

| CI=confidence interval, NE=not estimable |

| a | Efficacy-evaluable population for this expansion cohort is defined as all eligible participants who received                                         
 any study treatment and have at least one post-baseline efficacy assessment, or who discontinue study treatment due to progressive disease or death. |

| b | Majority of patients (n=21) were still on treatment at time of DCO. |

| c | In the 50mg BID cohort, one unconfirmed responder remains on treatment. In the 50mg QD cohort, one unconfirmed 
 responder became a confirmed responder after the DCO, increasing the cORR to 32%.                              |

| d | Unconfirmed best overall response. |

| e | Includes two patients with radiological progressive disease and two patients who had clinical progression 
 before the first scan.                                                                                    |

| f | The safety-evaluable population included all dose expansion enrolled patients who received any amount of any 
 study treatment.                                                                                             |

Gilead Opt-inDecision On February 18, 2025, we announced that the time-limited exclusive option of Gilead Sciences, Inc. (“Gilead”) to the casdatifan program has expired without exercise by Gilead. As a result, Gilead has no future rights to casdatifan; we retain full global development and commercial rights, subject to Taiho Pharmaceutical Co., Ltd.’s option right for its territory, which is limited to Japan and certain other Asian countries (excluding China).

S-2

Certain Preliminary Financial Information (Unaudited) As of December 31, 2024, we estimate that we had approximately $992 million in cash, cash equivalents and marketable securities. This estimate of our cash, cash equivalents and marketable securities balance is preliminary and subject